Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder

Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults


  • The P-III SUNRISE 1 (Study 304) study involves assessing of DAYVIGO (lemborexant, 5 or 10 mg) vs an active comparator or PBO in 1,006 patients with insomnia disorder aged 55 years of age or older
  • Results of P-III study@ 5/10 mg of DAYVIGO: headache (6.4%, 4.9 % vs 6.2%, 5.3%), somnolence (4.1%, 7.1% vs 1.9%, 1.5%), published in JAMA Network Open
  • Lemborexant is a candidate targeted for inhibiting orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2) and has also received the US FDA’s approval on Dec 20 , 2019 for patients to treat insomnia and will be available in 90 days post-approval

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance